menu | HOME | BUCKS | FAQs | HISTORY | IMAGES | INDUSTRY | LEGAL | LINKS | MANIFESTO | MEDICINE | RECREATION | WARRIORS | WHY |
submenu | MEDICINE | STUDY (1) | SCIENCE (1) | SCIENCE (2) |

MEDICAL HEMP

( marijuana study )

HONK FOR HEMP THUMBS UP GRAPHIC
Hemp of Northeast Kansas

SHORT-TERM EFFECTS OF CANNABINOIDS ON HIV-1 VIRAL LOAD

Donald Abrams, Roslyn J Leiser, Starley B Shade, Joan Hiton, Tarek Elberk
and the THC Study Team, University of California, San Francisco

INTRODUCTION

METHODS

INCLUSION CRITERIA

EXCLUSION CRITERIA

PATIENT CHARACTERISTICS

  • Clinical Characteristics (N=67)

  • Randomization by Protease Inhibitor and Study Arm (N =67)
    Protease Inhibitor

    Indivanir
    Nelfinavir
    Total
    Marijuana

    9 (13%)
    12 (18%)
    21 (31%)
    Dronabinal

    12 (18%)
    13 (19%)
    25 (37%)
    Placebo

    9 (13%)
    12 (18%)
    21 (31%)
    Total

    30 (45%)
    37 (55%)
    67

  • There were no statistically significant differences in patient demographic or clinical characteristics by study arm

    RESULTS

    Repeated measures model adjusted for protease
    inhibitor, baseline viral load, and baseline CD4.

    SUMMARY

    COLLABORATIONS

    Supported by NIH grant DA/MH11607. Dronabinol and placebo provided by Roxane Laboratories

    THC Study Data for Michael

    Below is some information about your individual test results while you participated in the THC study. Please bear in mind that laboratory tests were perfomed in research laboratories and are not intended to be used for clinical purposes. We encourage you to share this information with your health care provider. If you or your provider have any questions please feel free to contact us.

    Dates enrolled in study: 6/4/99-6/29/99

    Your randomly assigned study treatment was marinol

    Viral Load:

    During your stay in the GCRC your viral load was drawn ten times. The first two results were obtained before you started your study treatment. This graph represents your viral load results during the time you were in the GCRC and on your two follow up visits (if you attended them). If no line appears on this graph your viral load was undetectable (<50) during the entire study.

    CD4 (T-cell):

    Your CD4 count was measured five times in the GCRC and once at the three week follow up. This graph represents your CD4 results.

    Testosterone Average:

    Your testosterone level was drawn four times while you were in the study. The average of these four values was 46O. The normal range for testosterone levels in the SFGH Clinical Laboratories is 270-1194 for men and 11-83 for women.

    Weight:

    When you entered the GCRC, you weighed 152 lbs. When you were discharged from the study, your weight was 155 lbs. This graph shows your weight over the time you spent in the GCRC.

    Percentage Body Fat:

    This graph shows your percentage of body fat during the time you were in the GCRC. If no graph appears here data was not available.

    Caloric Intake:

    This graph represents the amount of calories you took in each day while in the GCRC.